# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 501-510 of 582 results.
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Status: Recruiting
Last Changed: Jul 07, 2020
First Received: Oct 07, 2016
Disease(s): Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Intervention(s): Ibrutinib, Radiation Therapy, TLR9 Agonist SD-101
Locations: Stanford University, School of Medicine, Palo Alto, California, United States
Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies
Status: Recruiting
Last Changed: Mar 03, 2020
First Received: Nov 14, 2014
Disease(s): Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Intervention(s): REGN1979 multiple dose levels, Rituximab
Locations: University of California, Irvine, Orange, California, United States
Stanford University, Stanford, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel), Boston, Massachusetts, United States
Mayo Clinic, Rochester, Minnesota, United States
... and 5 other locations.
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Status: Recruiting
Last Changed: Mar 17, 2020
First Received: Nov 07, 2017
Disease(s): Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Aplastic Anemia, B-Cell Non-Hodgkin Lymphoma, CD40 Ligand Deficiency, Chronic Granulomatous Disease, Chronic Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Congenital Amegakaryocytic Thrombocytopenia, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Glanzmann Thrombasthenia, Immunodeficiency Syndrome, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Severe Aplastic Anemia, Shwachman-Diamond Syndrome, Sickle Cell Disease, T-Cell Non-Hodgkin Lymphoma, Thalassemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
Intervention(s): Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Locations: Roswell Park Cancer Institute, Buffalo, New York, United States
DS-3201b in Participants With Lymphomas
Status: Recruiting
Last Changed: May 13, 2020
First Received: Apr 08, 2016
Disease(s): Lymphoma, Malignant, Non-hodgkin Lymphoma
Intervention(s): DS-3201b
Locations: Yale University, New Haven, Connecticut, United States
Emory University, Atlanta, Georgia, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
... and 11 other locations.
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
Status: Recruiting
Last Changed: Dec 26, 2018
First Received: Dec 26, 2018
Disease(s): Cancer, Breast Cancer, Gastric Cancer, Renal Cancer, Prostate Cancer, Melanoma, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Glioblastoma, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, B-cell Lymphoma
Intervention(s): Blood draws
Locations: Service de NEURO-ONCOLOGIE du Groupement Hospitalier EST, Bron, France
Service d'ONCOLOGIE DIGESTIVE et HEPATOLOGIE de l'hôpital de la Croix-Rousse, Lyon, France
Service d'ONCOLOGIE DIGESTIVE et HEPATOLOGIE de l'Hôpital E. Herriot, Lyon, France
Service d'Oto-Rhino-Laryngologie de l'Hôpital de la Croix-Rousse, Lyon, France
Service d'Urologie de l'Hôpital E. Herriot, Lyon, France
... and 13 other locations.
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Status: Recruiting
Last Changed: Nov 03, 2020
First Received: Jun 18, 2009
Disease(s): Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Monoclonal B-Cell Lymphocytosis, Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia)
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Status: Recruiting
Last Changed: Oct 08, 2020
First Received: Sep 10, 2019
Disease(s): Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Intervention(s): IGM-2323, IGM-2323
Locations: Honor Health Research Institute, Phoenix, Arizona, United States
City of Hope, Duarte, California, United States
Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
NYU, New York, New York, United States
MSKCC, New York, New York, United States
... and 4 other locations.
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Status: Recruiting
Last Changed: Sep 09, 2020
First Received: Jul 05, 2017
Disease(s): NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer
Intervention(s): NIR178, PDR001
Locations: University of California, Los Angeles, Santa Monica, California, United States
H Lee Moffitt Cancer Center and Research Institute Inc, Tampa, Florida, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
MD Anderson Cancer Center/University of Texas, Houston, Texas, United States
... and 17 other locations.
LITT and Pembrolizumab in Recurrent Brain Metastasis
Status: Recruiting
Last Changed: Sep 16, 2020
First Received: Dec 05, 2019
Disease(s): Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer, Head and Neck Squamous Cell Cancer, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Brain Metastases, Adult
Intervention(s): LITT + Pembrolizumab
Locations: McKnight Brain Institute of the University of Florida, Gainesville, Florida, United States
Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Status: Recruiting
Last Changed: Aug 07, 2020
First Received: Apr 05, 2016
Disease(s): Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Myeloid Leukemia With Variant MLL Translocations, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Chemotherapy-Related Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Gene Mutation, Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
Intervention(s): Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Rituximab, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Locations: M D Anderson Cancer Center, Houston, Texas, United States